DE3783588T2 - Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. - Google Patents

Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.

Info

Publication number
DE3783588T2
DE3783588T2 DE8787902737T DE3783588T DE3783588T2 DE 3783588 T2 DE3783588 T2 DE 3783588T2 DE 8787902737 T DE8787902737 T DE 8787902737T DE 3783588 T DE3783588 T DE 3783588T DE 3783588 T2 DE3783588 T2 DE 3783588T2
Authority
DE
Germany
Prior art keywords
measured
broad
spectrum
streptomyces
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787902737T
Other languages
German (de)
English (en)
Other versions
DE3783588D1 (de
Inventor
Kozo Asano
Kazuhisa Fujimoto
Michio Ichimura
Isao Kawamoto
Makoto Morimoto
Hirofumi Nakano
Hiroshi Sano
Isami Takahashi
Fusao Tomita
Toru Yasuzawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE3783588D1 publication Critical patent/DE3783588D1/de
Publication of DE3783588T2 publication Critical patent/DE3783588T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8787902737T 1986-04-17 1987-04-17 Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. Expired - Lifetime DE3783588T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8903186 1986-04-17
JP9564986 1986-04-24
PCT/JP1987/000247 WO1987006265A1 (fr) 1986-04-17 1987-04-17 Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation

Publications (2)

Publication Number Publication Date
DE3783588D1 DE3783588D1 (de) 1993-02-25
DE3783588T2 true DE3783588T2 (de) 1993-06-09

Family

ID=26430476

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787902737T Expired - Lifetime DE3783588T2 (de) 1986-04-17 1987-04-17 Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.

Country Status (5)

Country Link
US (1) US4923990A (https=)
EP (1) EP0271581B1 (https=)
JP (1) JPH0684377B2 (https=)
DE (1) DE3783588T2 (https=)
WO (1) WO1987006265A1 (https=)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994578A (en) * 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
EP0318056A3 (en) * 1987-11-27 1990-12-19 Meiji Seika Kaisha Ltd. Novel antibiotics and process for preparing the same
JP2642165B2 (ja) * 1988-07-22 1997-08-20 協和醗酵工業株式会社 新規ｄｃ−８９化合物およびその製造法
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5008271A (en) * 1988-10-21 1991-04-16 Kyowa Hakko Kogyo Co., Ltd. DC-88A derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5248692A (en) * 1990-06-11 1993-09-28 Kyowa Hakko Kogyo Co., Ltd. DC-89 derivatives as anti-tumor agents
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
EP0468400B1 (en) * 1990-07-26 1996-08-14 Kyowa Hakko Kogyo Co., Ltd. DC-89 derivatives as antitumoral agents
US5258383A (en) * 1991-06-28 1993-11-02 Kyowa Hakko Kogyo Co., Ltd. DC-89 derivatives
JPH05279374A (ja) * 1992-03-31 1993-10-26 Sawao Murao スイダトレスチン及びその製造方法
US20040136908A1 (en) * 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
JP2008529556A (ja) * 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
RS52100B (sr) 2005-10-26 2012-06-30 Medarex, Inc. Postupci i jedinjenja za pripremu analoga cc-1065
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) * 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
JPS5774090A (en) * 1980-10-27 1982-05-10 Shionogi & Co Ltd Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production
US4423228A (en) * 1980-11-18 1983-12-27 The Upjohn Company Process for preparing N-(methyl-sulfonyl)-1,2,8,8a-cyclopropa[c]benzo[1,2-b:4,3-b']dipyrrol-4(5H)-one
US4400518A (en) * 1980-11-18 1983-08-23 The Upjohn Company Composition of matter and process
US4413132A (en) * 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4423229A (en) * 1980-11-18 1983-12-27 The Upjohn Company Composition of matter and process
US4423230A (en) * 1980-11-18 1983-12-27 The Upjohn Company Preparation of an intermediate for N-(methylsulfonyl)-1,2,8,8a-cyclopropa[c][1,2-b:-4,3-b']dipyrol-4(5H)-one
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
DE3750612T2 (de) * 1986-12-19 1995-03-02 Upjohn Co Cc-1065 analoge.

Also Published As

Publication number Publication date
EP0271581A4 (en) 1989-06-26
US4923990A (en) 1990-05-08
WO1987006265A1 (fr) 1987-10-22
EP0271581B1 (en) 1993-01-13
EP0271581A1 (en) 1988-06-22
DE3783588D1 (de) 1993-02-25
JPH0684377B1 (https=) 1994-10-26
JPH0684377B2 (ja) 1994-10-26

Similar Documents

Publication Publication Date Title
DE3783588T2 (de) Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.
DE68907876T2 (de) Substanz DC 113 und Verfahren zu ihrer Herstellung.
DE68922442T2 (de) DC-89-Verbindungen und Verfahren zu ihrer Herstellung.
DE1770204B1 (de) Adriamycin und dessen Salze mit pharmakologisch vertraeglichen anorganischen und organischen Saeuren sowie diese enthaltende therapeutische Zusammensetzungen
DE3887820T2 (de) Antibiotika, Benanomicine A und B und Dexylosylbenanomicin B, ihre Herstellung und Verwendung.
DE69011913T2 (de) Phthalinidderivat, pharmazeutische Zubereitung und Verwendung.
DE2754326A1 (de) Antibiotikum am-2282, verfahren zu seiner herstellung und arzneimittel
DE69020645T2 (de) Antitumor- und Antibiotikum-Substanz, ihre Herstellung und Verwendungen.
EP0318056A2 (en) Novel antibiotics and process for preparing the same
DE68912355T2 (de) Antibiotische Antitumor-Verbindung und Methode zu deren Herstellung.
DE69114252T2 (de) Reveromycin-a, herstellung und verwendung als antitumormittel sowie als fungizid.
DE2839668C2 (https=)
CH631740A5 (en) Process for the preparation of maytansinol and its derivatives
DE3136675A1 (de) Neues peptid und dessen herstellung
DE3885361T2 (de) Verbindung DC-107 und Verfahren zu deren Herstellung.
EP0304400B1 (de) Phenanthridinderivate, Verfahren zu ihrer Herstellung und Mittel zur Ausführung des Verfahrens
DE69106577T2 (de) UCF1 Verbindungen, deren Derivate und Verfahren zu ihrer Herstellung.
DE3687170T2 (de) Antitumorale antibiotika und deren herstellung.
DE69001554T2 (de) Polyzyklische Verbindungen und deren Herstellung.
DE69217000T2 (de) Antibakterielle Verbindung BE-24566B
DE3407979C2 (https=)
DE69523433T2 (de) Die verbindung ge3
DE69005899T2 (de) Karzinostatisches oder antitumorales Antibiotikum, Conagenin, seine Herstellung und seine Verwendungen.
DE2746209A1 (de) Neues antibiotikum und verfahren zu dessen herstellung
DE69006577T2 (de) Neue antibiotische chemische Substanz "DC 114-C".

Legal Events

Date Code Title Description
8364 No opposition during term of opposition